AACR18 Preview 5: is TGFβ an emerging cancer target?
In our fifth AACR preview of the annual meeting of 2018, we switch directions from a tumour type to explore a novel and emerging pathway of interest.
Each year we pick a different target to explore; this year it’s the turn of TGFβ.
There’s a lot going on here, both preclinically and clinically that should interest BSB readers who are keen to see new developments in the IO landscape.
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers